Chloe Atreya, MD, PhD

Gastrointestinal Oncology UCSF

Our Care Team

Chloe Atreya, MD, PhD

Emily Bergsland, MD

Eric Collisson, MD

Katie Kelley, MD

Andrew Ko, MD

Michael Korn, MD

Margaret Tempero, MD

Katherine Van Loon, MD, MPH

Alan Venook, MD

Chloe Atreya, MD, PhD
Gastrointestinal cancer specialist

Dr. Chloe E. Atreya specializes in gastrointestinal cancer, particularly colorectal cancer, at the UCSF Helen Diller Comprehensive Cancer Center. Her research focuses on the interplay of tumor genetics and response to therapies for colorectal cancer, with the goal of improving patient outcomes and quality of life by personalizing treatment.  

Originally from Ann Arbor, MI, she earned a BA in molecular biology and a Certificate in visual art from Princeton University. Dr. Atreya received her medical degree and Ph.D. in pharmacology at Yale University. Subsequently, she completed her internship and residency in internal medicine at University of Washington, Seattle and fellowship in medical oncology at UCSF, where she is now an Assistant Clinical Professor.  

Dr. Atreya is the recipient of numerous prestigious awards, including the American Cancer Society Postdoctoral Fellowship, Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator Award and Alliance for Clinical Trials in Oncology Foundation Investigator Award. In 2014 she earned a certificate in Advanced Training in Clinical Research from the UCSF Clinical & Translational Science Institute. She is the recipient of a National Cancer Institute/National Institutes of Health K08 Career Development Award for Targeting of Aberrant Signaling in Patient-Derived Colorectal Cancer Models. Dr. Atreya is a member of the American Society of Clinical Oncologists, American Association of Cancer Researchers and Alliance for Clinical Trials in Oncology, Gastrointestinal Committee.  

Selected Publications

  • Atreya CE, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, Stone S, Shokat KM, and Warren RS. PTEN Expression is Consistent in Colorectal Cancer Primaries and Metastases and Associates with Patient Survival. Cancer Medicine, Epub 06/10/2013
  • Ducker GS, Atreya CE, Simko JS, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DD, Settleman J, Shokat KM, Warren RS (2013) Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene PMID: 23542178
  • Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM (2012) Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. Invest New Drugs, (6) 2219-25. PMID: 22270257.
  • Kelley RK, Atreya CE, Venook AP and Febbo PG. Predictive Biomarkers in Advance of a Companion Drug: Ahead of Their Time? (2012) J Natl Compr Canc Netw. Commentary. 10(3):303-9. PMID: 22393192.
  • Atreya CE, Ostrem JM, and Kelley RK, KRAS and Colorectal Cancer: Shades of Gray (2012) Personalized Medicine in Oncology. Review. 1(6). Epub 12/20/2012.